STK

Columbia Seligman Premium Technology Growth Fund
STK
Market cap $547M

33.04 USD

-0.22

0.66%

Updated Oct 22, 10:47 AM EDT

1 day

-0.66%

5 days

-0.75%

1 month

0.18%

3 months

-1.14%

6 months

11.13%

Year to date

9.04%

1 year

26.01%

5 years

53.82%

About: Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

133% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 12

7% more funds holding

Funds holding: 56 [Q1] → 60 (+4) [Q2]

3% less capital invested

Capital invested by funds: $76.9M [Q1] → $74.9M (-$2.02M) [Q2]

1.33% less ownership

Funds ownership: 14.93% [Q1] → 13.59% (-1.33%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for STK.

See Analyst Rankings

Financial journalist opinion

Forget Tech Volatility: ‘Go Global' With This Steady 8.1% Payer

Closed-end funds (CEFs), with an average yield of around 8%, are terrific for just about any investor—especially those looking to their portfolios to help pay the bills.

Forget Tech Volatility: ‘Go Global' With This Steady 8.1% Payer

5 Best CEFs This Month For Nearly 9% Yield (July 2024)

For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.

5 Best CEFs This Month For Nearly 9% Yield (July 2024)

These 8%+ Dividends Are Beating Hedge Funds At Their Own Game

Hedge funds have a big problem: They can't beat the market anymore.

These 8%+ Dividends Are Beating Hedge Funds At Their Own Game

Columbia Seligman Premium Technology Growth Fund, Inc. Holds 14th Annual Meeting of Stockholders

MINNEAPOLIS--(BUSINESS WIRE)--Columbia Seligman Premium Technology Growth Fund, Inc. (the “Fund”) (NYSE: STK) today held its 14th Annual Meeting of Stockholders (the “Meeting”) in Minneapolis, Minnesota. Stockholders voted in favor of the recommendations of the Fund's Board of Directors (the “Board”) on each of two proposals at the Meeting. Specifically, Stockholders re-elected Directors Kathleen Blatz, Pamela G. Carlton and George S. Batejan and elected David M. Moffett, each for a term that w.

Columbia Seligman Premium Technology Growth Fund, Inc. Holds 14th Annual Meeting of Stockholders

PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, today announced completion of enrollment for two clinical trials evaluating its ropeginterferon alfa-2b-njft (BESREMi®). The Phase 2b EXCEED-ET trial (NCT05482971), which is evaluating the effectiv.

PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera

STK: This Tech Stock ETF Is Likely Due For A Pullback

Columbia Seligman Premium Technology Growth Fund focuses on leading tech stocks with strong returns since inception. Top holdings include Lam Research, Broadcom, and Microsoft, all potentially overbought and due for a pullback. Nvidia's massive rally could spark a tech stock selloff, making it a good time to sell and wait for a pullback.

STK: This Tech Stock ETF Is Likely Due For A Pullback

STK: A High Yield From Tech At A Discount

Columbia Seligman Premium Technology Growth Fund outperforms S&P 500 in total return due to the high distribution and capital appreciation captured. STK provides a majority focus on the tech sector. Future interest rate cuts may serve as a catalyst for growth as this means that tech companies will have a lower cost of borrowing to fuel new innovations and growth.

STK: A High Yield From Tech At A Discount

How To Analyze 8%-Yielding Tech CEFs

Every now and then, we have a “big-dividend shootout”—we pit two big payers against each other and see which one wins out.

How To Analyze 8%-Yielding Tech CEFs

Columbia Seligman Premium Technology Growth Fund Announces a Second Quarter Distribution: 9.25% Annual Rate for IPO Investors

BOSTON--(BUSINESS WIRE)--Today, Columbia Seligman Premium Technology Growth Fund, Inc. (NYSE: STK) (the Fund) declared a second-quarter distribution, pursuant to its managed distribution policy, in the amount of $0.4625 per share, which is equal to a quarterly rate of 2.3125% (9.25% annualized) of the $20.00 offering price in the Fund's initial public offering in November 2009. The second-quarter distribution of $0.4625 per share is equal to a quarterly rate of 1.4929% (5.97% annualized) of the.

Columbia Seligman Premium Technology Growth Fund Announces a Second Quarter Distribution: 9.25% Annual Rate for IPO Investors

Rare Opportunity In The Columbia Seligman Premium Technology Growth CEF

Large-cap technology stocks are finally seeing some limits to their upside after an epic 40%-plus run to all-time highs over the last year or so. So while the Magnificent 7 aren't quite as magnificent as they used to be, in some ways that can be an advantage to funds that write options. The Columbia Seligman Premium Technology Growth Fund has historically been the premier option-write technology fund among CEFs, typically trading at a double-digit premium.

Rare Opportunity In The Columbia Seligman Premium Technology Growth CEF

See News Rankings

Charts implemented using Lightweight Charts™